Overview

Gender

male

Investor Type

Investment Partner

Jonathan MacQuitty is the Chief Executive Officer at D2G Oncology. He has more than 15 years of operational experience in life science companies and over 14 years of venture capital experience. His directorships have included Adiana, Dicerna, Entelos, Guava, Gynesonics, Labcyte, ParAllele BioScience, Personalis, SFJ Pharmaceuticals and Sunesis. He joined Abingworth in 1999 as President and Director of the company’s US subsidiary, Abingworth Management Inc, and is based at the firm’s offices in Menlo Park, California. Before joining Abingworth he was an adviser to a Japanese venture capital firm. Between 1988 and 1997 he was CEO of GenPharm International, a biotech company in which Abingworth invested. Before this he held business development positions at Genencor and
Genentech. He has served on the Board of the Biotechnology Industry Organization. Jonathan has an MA in Chemistry from Oxford University, a PhD in Chemistry from the University of Sussex and an MBA from Stanford University. Jonathan is responsible for Abingworth’s Menlo Park office and focuses on West Coast deals.